Literature DB >> 21356076

Can NGOs regulate medicines markets? Social enterprise in wholesaling, and access to essential medicines.

Maureen Mackintosh1, Sudip Chaudhuri, Phares Gm Mujinja.   

Abstract

BACKGROUND: Citizens of high income countries rely on highly regulated medicines markets. However low income countries' impoverished populations generally struggle for access to essential medicines through out-of-pocket purchase on poorly regulated markets; results include ill health, drug resistance and further impoverishment. While the role of health facilities owned by non-governmental organisations (NGOs) in low income countries is well documented, national and international wholesaling of essential medicines by NGOs is largely unstudied. This article describes and assesses the activity of NGOs and social enterprise in essential medicines wholesaling.
METHODS: The article is based on a set of interviews conducted in 2006-8 with trading NGOs and social enterprises operating in Europe, India and Tanzania. The analysis applies socio-legal and economic perspectives on social enterprise and market regulation.
RESULTS: Trading NGOs can resist the perverse incentives inherent in medicines wholesaling and improve access to essential medicines; they can also, in definable circumstances, exercise a broader regulatory influence over their markets by influencing the behaviour of competitors. We explore reasons for success and failure of social enterprise in essential medicines wholesaling, including commercial manufacturers' market response; social enterprise traders' own market strategies; and patterns of market advantage, market segmentation and subsidy generated by donors.
CONCLUSIONS: We conclude that, in the absence of effective governmental activity and regulation, social enterprise wholesaling can improve access to good quality essential medicines. This role should be valued and where appropriate supported in international health policy design. NGO regulatory impact can complement but should not replace state action.

Entities:  

Year:  2011        PMID: 21356076      PMCID: PMC3058036          DOI: 10.1186/1744-8603-7-4

Source DB:  PubMed          Journal:  Global Health        ISSN: 1744-8603            Impact factor:   4.185


  5 in total

1.  Reprivatizing pharmaceutical supplies in Africa.

Authors:  M Turshen
Journal:  J Public Health Policy       Date:  2001       Impact factor: 2.222

2.  Competitive spillovers across non-profit and for-profit nursing homes.

Authors:  David C Grabowski; Richard A Hirth
Journal:  J Health Econ       Date:  2003-01       Impact factor: 3.883

3.  Commercial influence and global nongovernmental public action in health and pharmaceutical policies.

Authors:  Meri Koivusalo; Maureen Mackintosh
Journal:  Int J Health Serv       Date:  2011       Impact factor: 1.663

4.  Trust and the development of health care as a social institution.

Authors:  Lucy Gilson
Journal:  Soc Sci Med       Date:  2003-04       Impact factor: 4.634

5.  Financing of global health: tracking development assistance for health from 1990 to 2007.

Authors:  Nirmala Ravishankar; Paul Gubbins; Rebecca J Cooley; Katherine Leach-Kemon; Catherine M Michaud; Dean T Jamison; Christopher J L Murray
Journal:  Lancet       Date:  2009-06-20       Impact factor: 79.321

  5 in total
  8 in total

1.  Understanding health systems, health economies and globalization: the need for social science perspectives.

Authors:  Susan F Murray; Ramila Bisht; Rama Baru; Emma Pitchforth
Journal:  Global Health       Date:  2012-08-31       Impact factor: 4.185

2.  Government capacities and stakeholders: what facilitates ehealth legislation?

Authors:  Achim Lang
Journal:  Global Health       Date:  2014-01-13       Impact factor: 4.185

3.  On the margins of aid orthodoxy: the Brazil-Mozambique collaboration to produce essential medicines in Africa.

Authors:  Giuliano Russo; Lícia de Oliveira; Alex Shankland; Tânia Sitoe
Journal:  Global Health       Date:  2014-09-25       Impact factor: 4.185

4.  Quality assurance of medicines supplied to low-income and middle-income countries: poor products in shiny boxes?

Authors:  A Nebot Giralt; B Schiavetti; B Meessen; C Pouget; J M Caudron; B Marchal; P Massat; S Thys; R Ravinetto
Journal:  BMJ Glob Health       Date:  2017-03-29

5.  The Quality of Medicines Used in Children and Supplied by Private Pharmaceutical Wholesalers in Kinshasa, Democratic Republic of Congo: A Prospective Survey.

Authors:  Benedetta Schiavetti; Evelien Wynendaele; Bart De Spiegeleer; Geremie J Mbinze; Nicodème Kalenda; Roland Marini; Vera Melotte; Epco Hasker; Bruno Meessen; Raffaella Ravinetto; Josiane Van der Elst; Daniel Mutolo Ngeleka
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

6.  Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries.

Authors:  Kerlijn Van Assche; Ariadna Nebot Giralt; Jean Michel Caudron; Benedetta Schiavetti; Corinne Pouget; Achilleas Tsoumanis; Bruno Meessen; Raffaella Ravinetto
Journal:  BMJ Glob Health       Date:  2018-06-09

7.  "It is very difficult in this business if you want to have a good conscience": pharmaceutical governance and on-the-ground ethical labour in Ghana.

Authors:  Kate Hampshire; Simon Mariwah; Daniel Amoako-Sakyi; Heather Hamill
Journal:  Glob Bioeth       Date:  2022-07-26

8.  The Belgian commitment to pharmaceutical quality: a model policy to improve quality assurance of medicines available through humanitarian and development programs.

Authors:  Raffaella Ravinetto; Tim Roosen; Catherine Dujardin
Journal:  J Pharm Policy Pract       Date:  2018-04-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.